Ken Griffin Arrowhead Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 37,300 shares of ARWR stock, worth $697,883. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,300

Previous 46,300 19.44%

Holding current value

$697,883

Previous $1.2 Million 39.98%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $4.44 Million - $6.77 Million	229,133 Added 24.16%	1,177,577 $22.8 Million
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $4.52 Million - $5.83 Million	206,547 Added 27.84%	948,444 $24.7 Million
Q1 2024 May 15, 2024	BUY	$27.21 - $39.48 $18.6 Million - $27 Million	683,260 Added 1165.24%	741,897 $21.2 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $1.71 Million - $2.5 Million	-80,634 Reduced 57.9%	58,637 $1.79 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $11.9 Million - $16.4 Million	-454,761 Reduced 76.55%	139,271 $3.74 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $6.4 Million - $10.5 Million	-254,273 Reduced 29.97%	594,032 $21.2 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $4.84 Million - $7.87 Million	204,332 Added 31.73%	848,305 $21.5 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $2.53 Million - $3.67 Million	90,425 Added 16.34%	643,973 $26.1 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $5.33 Million - $8.69 Million	179,851 Added 48.13%	553,548 $18.3 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $4.83 Million - $8.79 Million	173,773 Added 86.92%	373,697 $13.2 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $5.41 Million - $9.56 Million	136,629 Added 215.86%	199,924 $9.19 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $1.74 Million - $2.46 Million	-29,868 Reduced 32.06%	63,295 $4.2 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $7.11 Million - $10.4 Million	-121,825 Reduced 56.67%	93,163 $5.82 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $12 Million - $17.4 Million	-192,675 Reduced 47.26%	214,988 $17.8 Million
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $6.55 Million - $9.66 Million	106,791 Added 35.49%	407,663 $27 Million
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $1.53 Million - $2.98 Million	34,890 Added 13.12%	300,872 $23.1 Million
Q3 2020 Nov 16, 2020	BUY	$33.21 - $51.27 $4.84 Million - $7.47 Million	145,752 Added 121.23%	265,982 $11.5 Million
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $704,508 - $1.17 Million	-26,972 Reduced 18.32%	120,230 $5.19 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $16,550 - $50,811	-805 Reduced 0.54%	147,202 $4.24 Million
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $2.42 Million - $6.29 Million	86,113 Added 139.13%	148,007 $9.39 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $1.21 Million - $1.61 Million	46,256 Added 295.79%	61,894 $1.74 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $1.03 Million - $1.7 Million	-59,095 Reduced 79.07%	15,638 $414,000
Q1 2019 May 15, 2019	SELL	$12.05 - $20.18 $241,964 - $405,214	-20,080 Reduced 21.18%	74,733 $0
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $80,539 - $147,730	-7,499 Reduced 7.33%	94,813 $1.18 Million
Q3 2018 Nov 13, 2018	SELL	$14.0 - $20.3 $6.98 Million - $10.1 Million	-498,682 Reduced 82.98%	102,312 $0
Q2 2018 Aug 10, 2018	BUY	$6.37 - $14.02 $3.67 Million - $8.07 Million	575,955 Added 2300.23%	600,994 $0
Q1 2018 May 11, 2018	SELL	$3.72 - $7.64 $66,476 - $136,526	-17,870 Reduced 41.65%	25,039 $181,000
Q4 2017 Feb 09, 2018	BUY	$3.14 - $4.5 $45,708 - $65,506	14,557 Added 51.34%	42,909 $158,000
Q3 2017 Nov 09, 2017	BUY	$1.69 - $4.33 $47,914 - $122,764	28,352	28,352 $123,000

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.98B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account